| Literature DB >> 35082824 |
Becky Siu Yin Li1,2, Carmen Wing Han Chan1, Minjie Li1, Irene Kit Yee Wong1, Yvonne Hoi Un Yu1,2.
Abstract
INTRODUCTION: Behavioral and psychological symptoms of dementia (BPSD) is the most prominent and distressing manifestation for older persons with dementia (PWD) and caregivers. Aromatherapy has demonstrated its effectiveness in managing BPSD in various studies. However, previous studies and systematic reviews have obtained inconsistent findings, and a review of qualitative studies is yet to be conducted.Entities:
Keywords: Aromatherapy; BPSD; Behavioral and psychological symptoms of dementia; Dementia; Essential oil
Year: 2021 PMID: 35082824 PMCID: PMC8739377 DOI: 10.1159/000519915
Source DB: PubMed Journal: Dement Geriatr Cogn Dis Extra ISSN: 1664-5464
PICO model for identification of English and Chinese search terms
| PICO model | Search terms | ||
|---|---|---|---|
| English MeSH | English keywords | Chinese search terms | |
| P (Population) − older persons with dementia | “Dementia,” “frontotemporal dementia,” “dementia, vascular,” “dementia, multi-infarct,” “neurocognitive disorders,” “cognition disorders,” “Alzheimer disease,” “cognitive dysfunction” | “dement*,” “Alzheimer* disease*,” “cognit* impairment*,” “major neurocognitive disorder*,” “neurocognitive disorder*” |
|
|
| |||
| I (Intervention) − aromatherapy | “Aromatherapy,” “plant oils,” “oils, volatile,” “odorants” | “aromatherap*,” “aromacare,” “essential oil*,” “aroma therap*,” “aroma-therap*,” “aroma*,” “plant* oil*” |
|
|
| |||
| C (Comparison) − no active treatment/usual care | − | − | − |
|
| |||
| O (Outcome) − BPSD | “Behavioral symptoms,” “depression,” “depressive disorder,” “mental disorders,” “psychomotor agitation,” “anxiety,” “anxiety disorders,” “psychotic disorders,” “aggression,” “apathy,” “movement disorders,” “sleep wake disorders,” “appetite,” “feeding and eating disorders” | “anxi*,” “behave*,” “BPSD,” “Behave* and psych* symptom* of dement*,” “behave* adj3 symptom*,” “psych* adj3 symptom*,” “neuropsych* adj3 symptom*,” “aggress* behave*,” “aggress*,” “agitat*,” “depress*,” “mental disorders,” “psychosis,” “apathy,” “disinhibit*,” “motor disturb*,” “night-time behave*,” “appetite,” “eat* adj3 problem*” |
|
MeSH, Medical Subject Headings; PICO, Population, Intervention, Comparison, and Outcome.
Inclusion and exclusion criteria for quantitative and qualitative studies
| Inclusion criteria | Quantitative studies | Qualitative studies |
|---|---|---|
| Participants | For PWD | |
| ≥60 years old | ||
| Intervention | Aromatherapy: an intervention with the use of single essential oil or essential oil blends, in any dosage, frequencies, and approaches | N/A |
| Comparator Outcomes | Placebo treatment, no active treatment, or usual care | N/A |
| Primary outcome | N/A | |
| Change in PWD's severity of BPSD symptoms | ||
| Phenomenon of interest | N/A | Explored caregivers' experience and perception on the effectiveness and safety of aromatherapy for PWD with BPSD and caregivers Taken place either in institutions (e.g., hospitals, residential care facilities) or in community (e.g., day-care facilities, PWD's homes) settings |
| N/A | ||
| Types of studies | All quantitative study design | |
|
| ||
| Participants | Not all PWD in the study with dementia | |
| Comparator Types of studies | N/A |
BPSD, behavioral and psychological symptoms of dementia; N/A, not applicable; PWD, older persons with dementia; QoL, quality of life.
Fig. 1PRISMA flowchart of study retrieval and selection process. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Methodological quality of RCTs
| Ballard et al. [ | Cameron et al. [ | Fu et al. [ | Fujii et al. [ | Lin et al. [ | Mascherona et al. [ | O'Connor et al. [ | Smallwood et al. [ | Turten Kaymaz and Ozdemir [ | Yang et al. [ | Yang et al. | Yoshiyama et al. [ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Was true randomization used for assignment of participants to treatment groups? | Y | Y | Y |
|
| Y | Y |
|
| Y |
|
|
|
| ||||||||||||
| Was allocation to treatment groups concealed? | Y | Y | Y |
|
| Y | Y | Y |
| Y | Y |
|
|
| ||||||||||||
| Were the treatment groups similar at the baseline? |
|
| Y | Y | Y |
|
| Y | Y | Y |
|
|
|
| ||||||||||||
| Were the participants blind to treatment assignment? | Y | Y |
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||
| Were those delivering treatment blind to treatment assignment? | Y | Y |
|
|
|
| Y | Y |
|
|
|
|
|
| ||||||||||||
| Were the outcome assessors blind to treatment assignment? | Y | Y | Y | Y |
| Y | Y | Y |
| Y | Y |
|
|
| ||||||||||||
| Were treatment groups treated identically other than the intervention of interest? |
|
|
|
| Y | Y | Y | Y | Y | Y | Y | Y |
|
| ||||||||||||
| Was the follow-up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
|
| ||||||||||||
| Were the participants analyzed in the groups to which they were randomized? | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
|
| ||||||||||||
| Were the outcomes measured in the same way for treatment groups? | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
|
| ||||||||||||
| Were outcomes measured in a reliable way? | Y |
| Y | Y |
| Y | Y | Y | Y | Y | Y | Y |
|
| ||||||||||||
| Was the appropriate statistical analysis used? | Y |
| Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
|
| ||||||||||||
| Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial? | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
Y, yes; N, no; U, unclear; NA, not applicable; RCT, randomized controlled trial [
Methodological quality of quasi-experimental studies
| Beshara and Giddings [ | Gray and Clair [ | Holmes et al. [ | Lee and Lee [ | Moorman Li et al. [ | Ogun-Semore [ | Snow et al. [ | Takeda et al. [ | Ukwuoma [ | Zalomonson et al. [ | |
|---|---|---|---|---|---|---|---|---|---|---|
| Is it clear in the study what is the “cause” and what is the “effect” (i.e., there is no confusion about which variable comes first)? | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
|
| ||||||||||
| Were the participants included in any comparisons similar? | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
|
| ||||||||||
| Were the participants included in any comparisons receiving similar treatment/care, other than the exposure or intervention of interest? | N | Y | Y | Y | Y | Y | Y | Y | Y | Y |
|
| ||||||||||
| Was there a control group? | N | N | N | Y | N | N | N | N | N | Y |
|
| ||||||||||
| Were there multiple measurements of the outcome both pre and post the intervention/exposure? | N | N | N | Y | U | U | Y | Y | N | N |
|
| ||||||||||
| Was the follow-up complete and if not, were differences between groups in terms of their follow-up adequately described and analyzed? | Y | Y | Y | Y | Y | N | Y | Y | Y | Y |
|
| ||||||||||
| Were the outcomes of participants included in any comparisons measured in the same way? | Y | Y | Y | Y | Y | U | Y | Y | Y | Y |
|
| ||||||||||
| Were the outcomes measured in a reliable way? | U | Y | Y | Y | Y | U | U | Y | N | Y |
|
| ||||||||||
| Was the appropriate statistical analysis used? | N | Y | Y | Y | Y | Y | Y | Y | Y | Y |
Y, yes; N, no; U, unclear; NA, not applicable [63].
Methodological quality of qualitative studies
| Johannessen [ | Kilstoff and Chenoweth [ | |
|---|---|---|
| Is there congruity between the stated philosophical perspective and the research methodology? | U | U |
| Is there congruity between the research methodology and the research question or objectives? | Y | Y |
| Is there congruity between the research methodology and the methods used to collect data? | Y | Y |
| Is there congruity between the research methodology and the representation and analysis of data? | Y | Y |
| Is there congruity between the research methodology and the interpretation of results? | Y | Y |
| Is there a statement locating the researcher culturally or theoretically? | N | N |
| Is the influence of the researcher on the research, and vice- versa, addressed? | N | N |
| Are participants, and their voices, adequately represented? | Y | Y |
| Is the research ethical according to current criteria for recent studies, and is there evidence of ethical | Y | U |
| approval by an appropriate body? | ||
| Do the conclusions drawn in the research report flow from the analysis, or interpretation, of the data? | Y | Y |
Y, yes; N, no; U, unclear; NA, not applicable [64].
Summary table of included quantitative studies
| Study | Design duration of study | Country/city setting | Symptom of BPSD sample | Intervention | Control | Effectiveness | Safety | Others |
|---|---|---|---|---|---|---|---|---|
| A. | 2-Armed Parallel 4 weeks | UK | Agitation | Aromatherapy topical application | Placebo topical application By a care assistant 2 times a day 1–2 min per time 10% sunflower oil | CMAI | 1 patient receiving aromatherapy topical application experienced 2 days diarrhea | Adherence: weighing the bottles weekly, result not described Theoretical basis: not described |
|
| ||||||||
| Lin et al. [ | 2-Armed Crossover | Hong Kong | Agitation | Aromatherapy inhalation By care and attention homes staff | Placebo inhalation By care and attention homes staff | CCMAI | No adverse event was reported | Adherence: not described Theoretical basis: not described |
|
| ||||||||
| Mascherona et al. [ | 2-Armed Parallel 8–14 days | Switzerland | General symptoms of BPSD | Aromatherapy inhalation and standard pharmacological treatment | Standard pharmacological treatment | NPI-NH | No adverse event was reported | Adherence: not described Theoretical basis: not described |
|
| ||||||||
| O'Connor et al. [ | 2-Armed | Australia Nursing homes | Agitation n = 64 | Aromatherapy topical application | Placebo topical application By nursing staff Whenever an agitated behavior was reported 2 min per time Jojoba oil 2 mL per time | Behavioral count Agitated behavior counts were lower with intervention than with control, approaching statistical significance ( | No adverse event was reported | Adherence: not described Theoretical basis: not described |
|
| ||||||||
| Smallwood et al. [ | 3-Armed Parallel 4 weeks | UK | Disordered behavior | Aromatherapy massage By aromatherapist 2 times per week | Placebo massage By aromatherapist 2 times per week 1 h per time Plain oil massage | were higher in all intervention than control periods but not to significantly different degrees | Negligible side effects | Adherence: not described Theoretical basis: not described |
|
| ||||||||
| Turten Kaymaz and Ozdemir [ | 2-Armed Parallel 4 weeks | Turkey | Agitation | Aromatherapy massage and inhalation | No intervention | CMAI | Negligible side effects | Adherence: Monitored by massage and inhalation monitoring form, fully compliance was reported Theoretical basis: not described |
|
| ||||||||
| Yang et al. [ | 2-Armed Parallel | Taiwan | Agitation, depression n = 56 | Aromatherapy massage | Delay intervention Regular activities Aromatherapy massage was provided after completion of study | CCMAI | 2 participants in the intervention group withdrew due to discomfort after the first aromatherapy massage session | Adherence: not described Theoretical basis: not described |
|
| ||||||||
| Yang et al. [ | 3-Armed Parallel | Taiwan | Agitation, depression | Aromatherapy acupressure 5 days per week, 1 time per day No longer than 15 min per time 2.5% lavender essential oil Aromatherapy topical application | No intervention | CMAI | Negligible side effects | Adherence: not described Theoretical basis: not described |
|
| ||||||||
| Yoshiyama et al. [ | 2-Armed Crossover | Japan | General symptoms of BPSD | Aromatherapy massage | Placebo massage By a single researcher and an aromatherapist 3 times per week 10 min per time Jojoba oil | CMAI | Negligible side effects | Adherence: not described Theoretical basis: not described |
|
| ||||||||
|
| ||||||||
|
| ||||||||
| Beshara and Giddings | One-group pretest-posttest | USA | Agitation | Aromatherapy inhalation 9:00 a.m. and 5:00 p.m. daily Monday through Saturday with Sundays having no essential oil treatments | − | MDS | Possible adverse effect not described | Adherence: not described Theoretical basis: not described |
|
| ||||||||
| Gray and Clair [ | Within-subjects 16 days | USA | Difficult-to-manage behaviors | Aromatherapy/ Placebo Inhalation | Videotape | Possible adverse effect not described | Adherence: not described Theoretical basis: not described | |
|
| ||||||||
| Holmes et al. [ | Within-subjects 2 weeks | UK | Agitation | Aromatherapy/placebo inhalation | PAS | Possible adverse effect not described | Adherence: not described Theoretical basis: not described | |
|
| ||||||||
| Lee and Lee [ | Nonequivalent control group 2 weeks | Korea | Anxiety, aggressive behavior, and wandering behavior n = 43 | Aromatherapy massage | Delay intervention After completing data collection, intervention was administered to the control group | RAID | Possible adverse effect not described | Adherence: not described Theoretical basis: not described |
|
| ||||||||
| Moorman Li et al. [ | One-group pretest-posttest | USA | Behavioral issues (restlessness/wandering, agitation, anger, and anxiety) | Aromatherapy inhalation 2 times per day 20 min per time | − | Behavior/intervention monthly flow record No. of behavioral issues was lower in the postintervention period, but did not reach statistical significance | No adverse effect reported | Adherence: not described Theoretical basis: not described |
|
| ||||||||
| Ogun-Semore [ | One-group pretest-posttest | USA. | Agitation | Aromatherapy inhalation | − | Agitation with unknown instrument | Possible adverse effect not described | Adherence: not described Theoretical basis: not described |
|
| ||||||||
| Snow et al. [ | Within-subjects | USA. | Agitation | Aromatherapy/placebo inhalation 3 times per day | Modified CMAI No treatment effect | Possible adverse effect not described | Adherence: not described Theoretical basis: not described | |
|
| ||||||||
| Takeda et al. [ | Within-subjects 20-day control +20-day intervention | Japan | Sleep disturbance | Aromatherapy/placebo inhalation By researcher | NPI | Possible adverse effect not described | Adherence: not described Theoretical basis: not described | |
|
| ||||||||
| Ukwuoma | One-group pretest-posttest | USA | Anxiety | Aromatherapy massage By a researcher 3 times a week 10 min per time | − | HAM-A | Possible adverse effect not described | Adherence: not described Theoretical basis: not described |
|
| ||||||||
| Zalomonson et al. [ | Nonequivalent control group Crossover 4 months: month 1 oil A on face→ month 2 oil A on foot → month 3 oil B on foot → month 4 oil B on face | Israel | General symptoms of BPSD | Aromatherapy topical application | Placebo topical application By nurses 3 times a day 1–2 min per time 2 drops sunflower seed oil | NPI | 1 patient with exacerbation of chronic pulmonary disease while on placebo, there were 20 reported adverse events during intervention period (3 nausea, 13 sleepiness, 1 gait instability, 2 skin irritation, 1 fall) | Adherence: adherence rate was |
RCTs, randomized controlled trials; PWD, persons with dementia; BPSD, behavioral and psychological symptoms of dementia; NPI, Neuropsychiatric Inventory; SD, standard deviation; CMAI, Cohen-Mansfield Agitation Inventory; PAS, Pittsburgh Agitation Scale; CSDD, Cornell Scale for Depression in Dementia; ZBI, Zarit Burden Interview.
Fig. 2Forest plot of meta-analysis to 2 RCTs with aromatherapy inhalation of 100% lavender essential oil using the results of NPI as outcome measure. RCTs, randomized controlled trials; NPI, Neuropsychiatric Inventory; CI, confidence interval; SD, standard deviation.
Summary table of included qualitative studies
| Study | Design Country/city Setting | Participants | Methodology | Phenomenon of interest | Aromatherapy procedure and implementation | Conclusion | Safety | Notes |
|---|---|---|---|---|---|---|---|---|
| Johannessen | Action research | Residents | Data collection | Experience and perception of incorporating aromatherapy in the care of residents with dementia who suffer from anxiety and disturbed sleep patterns | By nurses 1 time per day Overnight per time 12–15 drops lavender essential into a diffuser | Nurses experienced an aromatherapy diffuser with lavender a simple and effective caring modality for residents with dementia suffering from anxiety and disturbed sleep patterns As a natural remedy, lavender was viewed as an effective tool in the care of PWD | Possible adverse effect not described | Adherence: The staff were monitored by the researcher and any issues associated with the use of the specific oils were addressed and discussed Theoretical basis: not described |
|
| ||||||||
| Kilstoff and Chenoweth | Action research | Clients | Data collection | Experience and perception of a community-initiated aromatherapy hand treatment for the multicultural dementia day-care clients | By family caregivers and day-care staff 10–15 min per time Essential oil blend in pure oil base for hand massage | The aromatherapy hand massage was effective in improving clients' behaviors, emotions, and physical functioning | Possible adverse effect not described | Adherence: not described Theoretical basis: not described |
PWD, persons with dementia. CAM, complementary and alternative medicines.
Synthesized findings of meta-aggregation
| Findings | Categories | Synthesized findings |
|---|---|---|
| Unclear effect (C) | 1.1. Effectiveness in BPSD management | 1. Effectiveness for PWD |
|
| ||
| One feel distasteful (C) | 1.2. Effectiveness in other aspects | |
|
| ||
| Relaxing (U) | 2.1. Effectiveness in the emotion and caregiving aspects | 2. Effectiveness for caregivers |
|
| ||
| Vehicle to reconnect (C) | 2.2. Effectiveness in improving relationships between caregivers and PWD | |
|
| ||
| Interest in using essential oils after the project is completed (U) | 2.3. Effectiveness in promoting interest in aromatherapy | |
U, unequivocal (findings accompanied by an illustration, i.e., beyond a reasonable doubt and therefore not open to challenge); C, credible (findings accompanied by an illustration lacking clear association with it and therefore open to challenge); PWD, persons with dementia; BPSD, behavioral and psychological symptoms of dementia.